Therapeutic Solutions International Announces Reduction of COVID-19 Associated Cognitive Decline by QuadraMune® Nutraceutical in Animal Model

New Data Suggests Possible Efficacy of QuadraMune® in Treatment of COVID-19 “Brain Fog”

Therapeutic Solutions International announced today filing of a new patent covering data demonstrating QuadraMune administration reduces cognitive decline caused by administration of COVID-19 spike protein in mice.

In a series of experiments, mice were treated with artificially generated spike protein on a daily basis for 7 days in order to mimic infection with SARS-CoV-2, the virus responsible for COVID-19 disease. One group of mice received saline and two groups received a low and high dose of QuadraMune, a fourth group of mice received no treatment. Significant dose dependent preservation of cognitive activity was observed in mice receiving QuadraMune. Additionally, reduction of microglial activation, a sign of neural inflammation was reported.

QuadraMune is an immune modulating nutraceutical whose use in treatment of COVID-19 is covered by issued US Patent #11,229,674.

“The more we learn about COVID-19 brain after-effects, the more we see a consistent pattern of inflammatory cytokines and inflammatory cells eliciting changes that cause chronic brain degeneration,” said Dr. Thomas Ichim, Board Member of Therapeutic Solutions International and Co-Inventor of the patent. “We are enthusiastic about the current data, which shows preservation of brain function and reduction of inflammation. This data suggests the possibility of offering a nutraceutical approach to COVID-19 patients to protect their brains.”

COVID-19 associated brain changes have been shown to cause severe damage in certain individuals. In one recent peer reviewed study, COVID-19 brain pathology was shown to be similar to Alzheimer’s Disease¹.

“We are only now beginning to see the long-term consequences of COVID-19 infection. We believe that the potent anti-inflammatory and neuroregenerative effects of QuadraMune may be particularly useful in leveraging the body’s own mechanisms to mediate post-infection healing,” said Timothy Dixon, President and CEO of the Company.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Alzheimer's‐like signaling in brains of COVID‐19 patients - Reiken - - Alzheimer's & Dementia - Wiley Online Library

View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005474/en/